ARTICLE | Clinical News
GEN-003: Phase IIb data
October 10, 2016 7:00 AM UTC
Top-line data from a double-blind, U.S. Phase IIb trial in 131 patients with genital HSV-2 infection showed that 60 ug intramuscular GEN-003 containing 50 ug Matrix M given 3 times 21 days apart met t...